Greg Hoffman

Greg Hoffman has a diverse and extensive work experience in the field of biotechnology and biomedical research. Greg is currently serving as the Vice President of Discovery & Platform at Arbor Biotechnologies, where they lead a team responsible for uncovering novel gene editors and optimizing their activity for therapeutic applications. Prior to this, Greg was the Senior Director of Discovery at Obsidian Therapeutics, where they played a pivotal role in developing controllable cell and gene therapies using innovative technologies. Greg also served as the Senior Director and Head of Cell Technologies at Sana Biotechnology, Inc. Additionally, Greg has a significant tenure at Novartis Institutes for BioMedical Research, where they held the position of Investigator II - Sr. Investigator I and led the Technologies Targets and Leads group in Screening Sciences. During their time at Harvard Medical School, Greg worked as a Postdoctoral Fellow, focusing on the mechanisms of growth factor and nutrient regulation in biological systems.

Greg Hoffman received their Bachelor of Arts degree in Biochemistry from Cornell University. Greg later pursued further education at the same university, earning a PhD in Biophysics.